Springer Nature Ophthalmology (@SN_Ophthalmol) header
Springer Nature Ophthalmology (@SN_Ophthalmol) profile picture

Ophthalmology news, research, and analysis. Official @SpringerNature channel.

London, UK
Joined September 2023
Photo by Springer Nature Ophthalmology (@SN_Ophthalmol)Photo by Springer Nature Ophthalmology (@SN_Ophthalmol)Photo by Springer Nature Ophthalmology (@SN_Ophthalmol)Photo by Springer Nature Ophthalmology (@SN_Ophthalmol)Photo by Springer Nature Ophthalmology (@SN_Ophthalmol)Photo by Springer Nature Ophthalmology (@SN_Ophthalmol)Photo by Springer Nature Ophthalmology (@SN_Ophthalmol)Photo by Springer Nature Ophthalmology (@SN_Ophthalmol)Photo by Springer Nature Ophthalmology (@SN_Ophthalmol)Photo by Springer Nature Ophthalmology (@SN_Ophthalmol)
👁️ New models of care are emerging…Allied health professional–led keratoconus services: ✅ Improve efficiency ❓ Risk losing specialist inputWhich side are you on?💬 Join the debate 🔗 doi.org/10.1038/s41433-026-0… #Ophthalmology
1
31
👁️ Retinitis pigmentosa isn’t one story. This study looks at visual acuity across 4 rod phototransduction genes. Which factor matters most here: 🧬 Gene type ⏳ Disease stage 👤 Patient variability Drop your pick 👇 🔗 doi.org/10.1038/s41433-026-0…
1
32
👁️ Barriers to eye exams: Cost, access, awareness… and ______? This study explores patient experience + what prevents people attending. Add the missing barrier 👇 🔗 doi.org/10.1038/s41433-026-0… #Ophthalmology
15
👁️ Fellow eye effect—real or rare? Does treating one eye change the other? One word, how does it affect your practice?👇 🔗 doi.org/10.1038/s41433-026-0…
19
💉 Myth or fact? “Intravitreal drug efficacy is mainly about dose, not pharmacokinetics.” A new primer unpacks the key principles shaping real-world outcomes in ophthalmology. 👇 Myth or fact—what’s your take? 🔗 doi.org/10.1038/s41433-026-0… #Ophthalmology
14
🤖📣 “Large language models in medical advertising will ______.” Disrupt practice? Improve access? Raise concerns? This paper explores the emerging influence of AI on medical decision-making. 💬 Finish the sentence below 🔗 doi.org/10.1038/s41433-026-0… #AIinMedicine
13
🏥 Community eye clinics: game changer or growing pain? New study explores patient & staff experiences in community-based diagnostics for chronic eye conditions. 👍Improved access 👎 Service challenges Which stands out to you? 💬 🔗 doi.org/10.1038/s41433-026-0… #Ophthalmology
14
👁️ New data from the Phase 3 PULSAR trial (Week 96) High-dose aflibercept (8 mg) for nAMD shows promising efficacy & safety. 📊 What matters most in long-term AMD treatment? doi.org/10.1038/s41433-026-0…
0%Durability
0%Visual acuity gains
0%Safety Profile
0%Real-world feasibility
0 votes • Final results
31
🧠👓 Do contact lenses have to correct vision to influence eye growth?nature.com/articles/s41433-0…
20
As biosimilars mature, an uncomfortable question comes into focus: are phase III retinal trials still necessary? Rethinking phase III trials in retinal biosimilars: Do we still need them? nature.com/articles/s41433-0…
1
34